Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy; Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy.
Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Clin Genitourin Cancer. 2018 Dec;16(6):482-484. doi: 10.1016/j.clgc.2018.07.014. Epub 2018 Jul 20.
Patients who receive a diagnosis of metastatic castration-sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.
患有转移性去势敏感性前列腺癌（CSPC）的患者具有不同的疾病表型。其中一些患者为初发 CSPC，但另一些患者为晚期诊断，还有一些患者在转移诊断前几年接受了前列腺切除术。我们分析了 CSPC 近期临床试验中存在的这些差异，并评估了它们对结果的可能影响。
